Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""ANAPLASTIC lymphoma kinase"" wg kryterium: Temat


Tytuł :
The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
Autorzy :
Kawauchi D; Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.; Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Takahashi M; Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.; Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
Satomi K; Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.
Yamamuro S; Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.; Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan.
Kobayashi T; Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.; Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Uchida E; Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.; Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Hidaka-City, Japan.
Honda-Kitahara M; Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
Narita Y; Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
Iwadate Y; Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Ichimura K; Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
Tomiyama A; Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.; Department of Neurosurgery, National Defense Medical College, Tokorozawa, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 Jun; Vol. 112 (6), pp. 2442-2453. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase/*genetics
Brain Neoplasms/*drug therapy
Carbazoles/*administration & dosage
Glioblastoma/*drug therapy
Piperidines/*administration & dosage
Pyrimidines/*administration & dosage
STAT3 Transcription Factor/*metabolism
Sulfones/*administration & dosage
Administration, Oral ; Anaplastic Lymphoma Kinase/metabolism ; Animals ; Brain Neoplasms/genetics ; Brain Neoplasms/metabolism ; Carbazoles/pharmacology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Drug Resistance, Neoplasm/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Glioblastoma/genetics ; Glioblastoma/metabolism ; Humans ; Mice ; Piperidines/pharmacology ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacology ; Pyrimidines/pharmacology ; Signal Transduction/drug effects ; Sulfones/pharmacology ; Temozolomide/pharmacology ; Treatment Outcome ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Atypical course of anaplastic large cell lymphoma with positive anaplastic lymphoma kinase.
Autorzy :
Mrowiec S
Jabłońska B
Rozłucka L
Janoska-Gawrońska A
Pająk J
Holecki M
Pokaż więcej
Źródło :
Polish archives of internal medicine [Pol Arch Intern Med] 2021 Apr 29; Vol. 131 (4), pp. 381-383. Date of Electronic Publication: 2021 Feb 24.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase*/genetics
Lymphoma, Large-Cell, Anaplastic*/diagnostic imaging
Adult ; Humans ; Male
Czasopismo naukowe
Tytuł :
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Autorzy :
Remon J; Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain.
Pignataro D; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy.
Novello S; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy. Electronic address: .
Passiglia F; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy.
Pokaż więcej
Źródło :
Cancer treatment reviews [Cancer Treat Rev] 2021 Apr; Vol. 95, pp. 102178. Date of Electronic Publication: 2021 Mar 10.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Gene Rearrangement*
Molecular Targeted Therapy*
Anaplastic Lymphoma Kinase/*genetics
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Protein-Tyrosine Kinases/*genetics
Proto-Oncogene Proteins/*genetics
Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Proto-Oncogene Proteins/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Pharmacological inhibition of focal adhesion kinase 1 (FAK1) and anaplastic lymphoma kinase (ALK) identified via kinome profile analysis attenuates lipopolysaccharide-induced endothelial inflammatory activation.
Autorzy :
Dayang EZ; Department of Pathology and Medical Biology, Medical Biology Section, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Luxen M; Department of Pathology and Medical Biology, Medical Biology Section, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Kuiper T; Department of Pathology and Medical Biology, Medical Biology Section, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Yan R; Department of Pathology and Medical Biology, Medical Biology Section, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Rangarajan S; PamGene International B.V., 's-Hertogenbosch, the Netherlands.
van Meurs M; Department of Pathology and Medical Biology, Medical Biology Section, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Moser J; Department of Pathology and Medical Biology, Medical Biology Section, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Molema G; Department of Pathology and Medical Biology, Medical Biology Section, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 Jan; Vol. 133, pp. 111073. Date of Electronic Publication: 2020 Dec 13.
Typ publikacji :
Journal Article; Video-Audio Media
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Anti-Inflammatory Agents/*pharmacology
Focal Adhesion Kinase 1/*antagonists & inhibitors
Human Umbilical Vein Endothelial Cells/*drug effects
Inflammation/*prevention & control
Lipopolysaccharides/*toxicity
Protein Kinase Inhibitors/*pharmacology
Aminopyridines/pharmacology ; Anaplastic Lymphoma Kinase/genetics ; Anaplastic Lymphoma Kinase/metabolism ; Focal Adhesion Kinase 1/genetics ; Focal Adhesion Kinase 1/metabolism ; Gene Expression Profiling ; HL-60 Cells ; Human Umbilical Vein Endothelial Cells/enzymology ; Humans ; Inflammation/enzymology ; Inflammation/genetics ; Protein Array Analysis ; Proto-Oncogene Proteins/antagonists & inhibitors ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins/metabolism ; Pyridones/pharmacology ; Pyrimidines/pharmacology ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors ; Receptor Protein-Tyrosine Kinases/genetics ; Receptor Protein-Tyrosine Kinases/metabolism ; Signal Transduction ; Sulfones/pharmacology ; Time Factors ; Transcriptome
Czasopismo naukowe
Tytuł :
Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.
Autorzy :
Guo M; Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Zuo D; Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Zhao T; Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Li X; Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Cao J; Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Qiu Y; Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Wei S; Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Zhai X; Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Mar 15; Vol. 214, pp. 113259. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Protein-Tyrosine Kinases/*antagonists & inhibitors
Proto-Oncogene Proteins/*antagonists & inhibitors
Pyrimidines/*pharmacology
Anaplastic Lymphoma Kinase/genetics ; Anaplastic Lymphoma Kinase/metabolism ; Cell Line, Tumor ; Dose-Response Relationship, Drug ; Humans ; Models, Molecular ; Molecular Structure ; Mutation/drug effects ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Protein-Tyrosine Kinases/genetics ; Protein-Tyrosine Kinases/metabolism ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins/metabolism ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology.
Autorzy :
Kashima J; Departments of Diagnostic Pathology.; Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yoshida M; Departments of Diagnostic Pathology.
Jimbo K; Breast Surgery.
Izutsu K; Hematology.; Rare Cancer Center, National Cancer Center Hospital.
Ushiku T; Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yonemori K; Breast and Medical Oncology.; Rare Cancer Center, National Cancer Center Hospital.
Yoshida A; Departments of Diagnostic Pathology.; Rare Cancer Center, National Cancer Center Hospital.
Pokaż więcej
Źródło :
The American journal of surgical pathology [Am J Surg Pathol] 2021 Mar 01; Vol. 45 (3), pp. 347-355.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anaplastic Lymphoma Kinase/*analysis
Breast Diseases/*enzymology
Histiocytosis/*enzymology
Adolescent ; Adult ; Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Anaplastic Lymphoma Kinase/genetics ; Biomarkers/analysis ; Breast Diseases/genetics ; Breast Diseases/pathology ; Breast Diseases/therapy ; Chemotherapy, Adjuvant ; Female ; Gene Rearrangement ; Histiocytosis/genetics ; Histiocytosis/pathology ; Histiocytosis/therapy ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Kinesin/genetics ; Mastectomy ; Middle Aged ; Protein Kinase Inhibitors/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Discovery of a PROTAC targeting ALK with in vivo activity.
Autorzy :
Yan G; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, China; Department of Hepatobiliary Pancreatic Surgery, Henan Provincial People's Hospital, Henan University, Zhengzhou, China.
Zhong X; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Yue L; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Pu C; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Shan H; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Lan S; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Zhou M; Engineering Research Center for the Development and Application of Ethnic Medicine and TCM, Ministry of Education & State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China.
Hou X; College of Pharmacy, Xinxiang Medical University, Xinxiang, China.
Yang J; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Li R; State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Feb 15; Vol. 212, pp. 113150. Date of Electronic Publication: 2021 Jan 02.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Discovery*
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Agents/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Sulfones/*pharmacology
Anaplastic Lymphoma Kinase/metabolism ; Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Female ; Humans ; Ligands ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Molecular Structure ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/metabolism ; Neoplasms, Experimental/pathology ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Rats ; Rats, Sprague-Dawley ; Structure-Activity Relationship ; Sulfones/chemical synthesis ; Sulfones/chemistry ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
A genome-scale CRISPR screen reveals factors regulating Wnt-dependent renewal of mouse gastric epithelial cells.
Autorzy :
Murakami K; Division of Epithelial Stem Cell Biology, Cancer Research Institute, Kanazawa University, Kakuma-machi, 924-1192 Kanazawa, Japan; .
Terakado Y; Division of Epithelial Stem Cell Biology, Cancer Research Institute, Kanazawa University, Kakuma-machi, 924-1192 Kanazawa, Japan.
Saito K; Division of Epithelial Stem Cell Biology, Cancer Research Institute, Kanazawa University, Kakuma-machi, 924-1192 Kanazawa, Japan.
Jomen Y; Division of Epithelial Stem Cell Biology, Cancer Research Institute, Kanazawa University, Kakuma-machi, 924-1192 Kanazawa, Japan.
Takeda H; Laboratory of Molecular Genetics, National Cancer Center Research Institute, Chuo-ku, 104-0045 Tokyo, Japan.
Oshima M; Division of Genetics, Cancer Research Institute, Nano-Life Science Institute, Kanazawa University, Kakuma-machi, 920-1192 Kanazawa, Japan.
Barker N; Division of Epithelial Stem Cell Biology, Cancer Research Institute, Kanazawa University, Kakuma-machi, 924-1192 Kanazawa, Japan; .; Epithelial Stem Cell Group, Agency for Science, Technology and Research Institute of Molecular and Cell Biology, 138673 Singapore, Singapore.; Agency for Science, Technology and Research Institute of Medical Biology, 276543 Singapore, Singapore.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2021 Jan 26; Vol. 118 (4).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adult Stem Cells/*metabolism
Anaplastic Lymphoma Kinase/*genetics
Epithelial Cells/*metabolism
Gene Editing/*methods
Organoids/*metabolism
RNA-Binding Proteins/*genetics
Wnt Signaling Pathway/*genetics
Adenomatous Polyposis Coli Protein/genetics ; Adenomatous Polyposis Coli Protein/metabolism ; Adult Stem Cells/cytology ; Anaplastic Lymphoma Kinase/metabolism ; Animals ; CRISPR-Cas Systems ; Cell Proliferation ; Epithelial Cells/cytology ; Gastric Mucosa/cytology ; Gastric Mucosa/metabolism ; Gene Expression Regulation ; Gene Library ; Glycogen Synthase Kinase 3 beta/genetics ; Glycogen Synthase Kinase 3 beta/metabolism ; HEK293 Cells ; Humans ; Interleukins/genetics ; Interleukins/metabolism ; Mice ; Organoids/cytology ; RNA-Binding Proteins/metabolism ; Receptors, G-Protein-Coupled/genetics ; Receptors, G-Protein-Coupled/metabolism ; Stomach/cytology
Czasopismo naukowe
Tytuł :
Identification of novel ALK rearrangements in gynecologic clear cell carcinoma.
Autorzy :
Yang C; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zhang L; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Love-Gregory L; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Sun L; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Hagemann IS; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Cao D; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Jan 15; Vol. 148 (2), pp. 459-468. Date of Electronic Publication: 2020 Oct 19.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma, Clear Cell/*genetics
Anaplastic Lymphoma Kinase/*genetics
Genital Neoplasms, Female/*genetics
Adenocarcinoma, Clear Cell/enzymology ; Adenocarcinoma, Clear Cell/pathology ; Adult ; Aged ; Aged, 80 and over ; Anaplastic Lymphoma Kinase/biosynthesis ; Female ; Gene Dosage ; Gene Rearrangement ; Genital Neoplasms, Female/enzymology ; Genital Neoplasms, Female/pathology ; Humans ; Immunohistochemistry ; Middle Aged ; Nerve Tissue Proteins/genetics ; Oncogene Proteins, Fusion/genetics ; Translocation, Genetic
Czasopismo naukowe
Tytuł :
Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement.
Autorzy :
Khanlari M; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hao S; Department of Pathology and Genomic Medicine, Methodist Hospital, Houston, TX, USA.
Gong Y; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Li S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Miranda RN; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lin P; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Iyer S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yin CC; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xie W; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vega F; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Medeiros LJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xu J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2021 Jan; Vol. 192 (1), pp. e17-e21. Date of Electronic Publication: 2020 Nov 20.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Gene Rearrangement*
Anaplastic Lymphoma Kinase/*analysis
Lymphoma, Large-Cell, Anaplastic/*genetics
Proto-Oncogene Proteins c-myc/*genetics
Anaplastic Lymphoma Kinase/genetics ; Female ; Humans ; Lymphoma, Large-Cell, Anaplastic/pathology ; Male ; Middle Aged ; Proto-Oncogene Proteins c-myc/analysis
Raport
Tytuł :
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Autorzy :
Naito T; Department of Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan.
Shiraishi H; Department of Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan.
Fujiwara Y; Department of Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan.
Pokaż więcej
Źródło :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 Jan 01; Vol. 51 (1), pp. 37-44.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Mutation*
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Central Nervous System Neoplasms/*secondary
Lactams, Macrocyclic/*therapeutic use
Lung Neoplasms/*drug therapy
Organophosphorus Compounds/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Pyrimidines/*therapeutic use
Anaplastic Lymphoma Kinase/analysis ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Crizotinib/therapeutic use ; Drug Resistance, Neoplasm/genetics ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology
Czasopismo naukowe
Tytuł :
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients.
Autorzy :
Chang GC; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Blvd., Taichung, 407, Taiwan.; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, 112, Taiwan.; Institute of Biomedical Sciences, National Chung Hsing University, Taichung, 402, Taiwan.; Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, 402, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan.; Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan.
Yang TY; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Blvd., Taichung, 407, Taiwan.; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, 112, Taiwan.
Chen KC; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Blvd., Taichung, 407, Taiwan.; Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, 402, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan.; Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan.; Department of Applied Chemistry, National Chi Nan University, Nantou, 545, Taiwan.
Hsu KH; Division of Critical Care and Respiratory Therapy, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, 407, Taiwan.
Huang YH; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Blvd., Taichung, 407, Taiwan.; Institute of Biomedical Sciences, National Chung Hsing University, Taichung, 402, Taiwan.
Su KY; Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, 100, Taiwan.
Yu SL; Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, 100, Taiwan.; Center of Genomic Medicine, National Taiwan University College of Medicine, Taipei, 100, Taiwan.; Department of Pathology and Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.; Center for Optoelectronic Biomedicine, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.
Tseng JS; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Blvd., Taichung, 407, Taiwan. .; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, 112, Taiwan. .; Institute of Biomedical Sciences, National Chung Hsing University, Taichung, 402, Taiwan. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Dec 03; Vol. 10 (1), pp. 21063. Date of Electronic Publication: 2020 Dec 03.
Typ publikacji :
Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase/*genetics
B7-H1 Antigen/*genetics
Carcinoma, Non-Small-Cell Lung/*enzymology
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*enzymology
Lung Neoplasms/*genetics
Mutation/*genetics
Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Cigarette Smoking/adverse effects ; Disease-Free Survival ; Female ; Humans ; Lung Neoplasms/drug therapy ; Male ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł :
ALK-transformed mature T lymphocytes restore early thymus progenitor features.
Autorzy :
Congras A; INSERM, UMR1037 CRCT, F-31000, Toulouse, France.; Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000, Toulouse, France.; CNRS, ERL5294 UMR1037 CRCT, F-31000, Toulouse, France.; Equipe Labellisée LIGUE 2017, Toulouse, France.
Hoareau-Aveilla C; INSERM, UMR1037 CRCT, F-31000, Toulouse, France.; Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000, Toulouse, France.; CNRS, ERL5294 UMR1037 CRCT, F-31000, Toulouse, France.; Equipe Labellisée LIGUE 2017, Toulouse, France.
Caillet N; INSERM, UMR1037 CRCT, F-31000, Toulouse, France.; Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000, Toulouse, France.; CNRS, ERL5294 UMR1037 CRCT, F-31000, Toulouse, France.; Equipe Labellisée LIGUE 2017, Toulouse, France.
Tosolini M; INSERM, UMR1037 CRCT, F-31000, Toulouse, France.; Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000, Toulouse, France.; CNRS, ERL5294 UMR1037 CRCT, F-31000, Toulouse, France.; Pôle Technologique du CRCT, Plateau Bioinformatique, Toulouse, France.
Villarese P; Hematology and INSERM1151, Institut Necker-Enfants Malades, University Sorbonne Paris Cité at Descartes and Assistance Publique-Hopitaux de Paris, Paris, France.
Cieslak A; Hematology and INSERM1151, Institut Necker-Enfants Malades, University Sorbonne Paris Cité at Descartes and Assistance Publique-Hopitaux de Paris, Paris, France.
Rodriguez L; Etablissement Français du Sang, Nouvelle Aquitaine, INSERM U1035, Université de Bordeaux, Bordeaux, France.
Asnafi V; Hematology and INSERM1151, Institut Necker-Enfants Malades, University Sorbonne Paris Cité at Descartes and Assistance Publique-Hopitaux de Paris, Paris, France.
Macintyre E; Hematology and INSERM1151, Institut Necker-Enfants Malades, University Sorbonne Paris Cité at Descartes and Assistance Publique-Hopitaux de Paris, Paris, France.
Egger G; Department of Pathology, Medical University Vienna, Vienna, Austria.; Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.
Brousset P; INSERM, UMR1037 CRCT, F-31000, Toulouse, France.; Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000, Toulouse, France.; CNRS, ERL5294 UMR1037 CRCT, F-31000, Toulouse, France.; Equipe Labellisée LIGUE 2017, Toulouse, France.; Institut Carnot Lymphome, Toulouse, France.; Laboratoire d'Excellence Toulouse Cancer and after Cancer (Labex TOUCAN), Toulouse, France.
Lamant L; INSERM, UMR1037 CRCT, F-31000, Toulouse, France.; Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000, Toulouse, France.; CNRS, ERL5294 UMR1037 CRCT, F-31000, Toulouse, France.; Equipe Labellisée LIGUE 2017, Toulouse, France.; Institut Carnot Lymphome, Toulouse, France.; Laboratoire d'Excellence Toulouse Cancer and after Cancer (Labex TOUCAN), Toulouse, France.; European Research Initiative on ALK-Related Malignancies, Cambridge, United Kingdom, Vienna, Austria, and Toulouse, France.
Meggetto F; INSERM, UMR1037 CRCT, F-31000, Toulouse, France.; Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000, Toulouse, France.; CNRS, ERL5294 UMR1037 CRCT, F-31000, Toulouse, France.; Equipe Labellisée LIGUE 2017, Toulouse, France.; Hematology and INSERM1151, Institut Necker-Enfants Malades, University Sorbonne Paris Cité at Descartes and Assistance Publique-Hopitaux de Paris, Paris, France.; Institut Carnot Lymphome, Toulouse, France.; Laboratoire d'Excellence Toulouse Cancer and after Cancer (Labex TOUCAN), Toulouse, France.; European Research Initiative on ALK-Related Malignancies, Cambridge, United Kingdom, Vienna, Austria, and Toulouse, France.
Pokaż więcej
Źródło :
The Journal of clinical investigation [J Clin Invest] 2020 Dec 01; Vol. 130 (12), pp. 6395-6408.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anaplastic Lymphoma Kinase/*biosynthesis
CD4-Positive T-Lymphocytes/*enzymology
Cell Transformation, Neoplastic/*metabolism
Lymphoma, Large-Cell, Anaplastic/*enzymology
Neoplastic Stem Cells/*enzymology
Thymus Gland/*enzymology
Anaplastic Lymphoma Kinase/genetics ; Animals ; CD4-Positive T-Lymphocytes/pathology ; Cell Line, Tumor ; Cell Transformation, Neoplastic/genetics ; Cell Transformation, Neoplastic/pathology ; Female ; Humans ; Lymphoma, Large-Cell, Anaplastic/genetics ; Lymphoma, Large-Cell, Anaplastic/pathology ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Neoplastic Stem Cells/pathology ; Thymus Gland/pathology
Czasopismo naukowe
Tytuł :
Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash.
Autorzy :
Anderson BE; St. Luke's Regional Cancer Center, St. Luke's Hospital, Duluth, MN, USA.
Luczak TS; St. Luke's Regional Cancer Center, St. Luke's Hospital, Duluth, MN, USA.
Ries LM; St. Luke's Regional Cancer Center, St. Luke's Hospital, Duluth, MN, USA.
Hoefs GE; St. Luke's Regional Cancer Center, St. Luke's Hospital, Duluth, MN, USA.
Silva-Benedict AC; St. Luke's Regional Cancer Center, St. Luke's Hospital, Duluth, MN, USA.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2020 Dec; Vol. 26 (8), pp. 2028-2030. Date of Electronic Publication: 2020 May 31.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Adenocarcinoma of Lung/*drug therapy
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Carbazoles/*adverse effects
Desensitization, Immunologic/*methods
Drug Hypersensitivity/*therapy
Exanthema/*chemically induced
Lung Neoplasms/*drug therapy
Piperidines/*adverse effects
Protein Kinase Inhibitors/*adverse effects
Aged ; Anaplastic Lymphoma Kinase/analysis ; Female ; Humans ; Lung Neoplasms/enzymology
Czasopismo naukowe
Tytuł :
Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
Autorzy :
Fukano R; Department of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Mori T; Department of Pediatrics, St. Marianna University School of Medicine Hospital, Kanagawa, Japan.
Sekimizu M; Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Choi I; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Kada A; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Saito AM; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Asada R; Innovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu, Japan.
Takeuchi K; Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.; Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Terauchi T; Department of Nuclear Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Tateishi U; Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Horibe K; Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Nagai H; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.; Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Dec; Vol. 111 (12), pp. 4540-4547. Date of Electronic Publication: 2020 Oct 28.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Carbazoles/*administration & dosage
Lymphoma, Large-Cell, Anaplastic/*drug therapy
Lymphoma, Large-Cell, Anaplastic/*enzymology
Piperidines/*administration & dosage
Protein Kinase Inhibitors/*administration & dosage
Administration, Oral ; Adult ; Aged ; Anaplastic Lymphoma Kinase/blood ; Carbazoles/adverse effects ; Carbazoles/pharmacokinetics ; Child ; Confidence Intervals ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Female ; Humans ; Japan ; Lymphoma, Large-Cell, Anaplastic/mortality ; Male ; Piperidines/adverse effects ; Piperidines/pharmacokinetics ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics ; Recurrence ; Survival Rate ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer.
Autorzy :
Shaw AT; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Bauer TM; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
de Marinis F; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Felip E; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Goto Y; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Liu G; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Mazieres J; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Kim DW; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Mok T; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Polli A; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Thurm H; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Calella AM; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Peltz G; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Solomon BJ; From the Massachusetts General Hospital Cancer Center (A.T.S.) and Pfizer (G.P.) - both in Boston; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (T.M.B.); European Institute of Oncology, IRCCS (F.M.), and Pfizer (A.P., A.M.C.) - both in Milan; Vall d'Hebron University Hospital and Institute of Oncology, International Oncology Bureau-Quirón, Barcelona (E.F.); National Cancer Center Hospital, Tokyo (Y.G.); Princess Margaret Cancer Centre, Toronto (G.L.); Toulouse University Hospital, Toulouse, France (J.M.); Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea (D.-W.K.); State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong (T.M.); Pfizer, La Jolla, CA (H.T.); and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.).
Pokaż więcej
Corporate Authors :
CROWN Trial Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Nov 19; Vol. 383 (21), pp. 2018-2029.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Crizotinib/*therapeutic use
Lactams, Macrocyclic/*therapeutic use
Lung Neoplasms/*drug therapy
Adult ; Aged ; Anaplastic Lymphoma Kinase/genetics ; Antineoplastic Agents/adverse effects ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Crizotinib/adverse effects ; Female ; Humans ; Hyperlipidemias/chemically induced ; Intention to Treat Analysis ; Lactams, Macrocyclic/adverse effects ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Mutation ; Survival Analysis
Czasopismo naukowe
Tytuł :
[Anaplastic lymphoma kinase-positive large B-cell lymphoma in a child].
Autorzy :
Wang S; Department of Pediatric Lymphoma, Beijing Boren Hospital, Beijing 100045, China.
Zhou CJ; Pathology Laboratory, Beijing Children's Hospital, Captal Medical University, National Center for Children's Health, Beijing 100045, China.
Zheng QL; Molecular Diagnostics Laboratory, Beijing Boren Hospital, Beijing 100045, China.
Zhang WQ; Department of Pediatric Lymphoma, Beijing Boren Hospital, Beijing 100045, China.
Hu B; Department of Pediatric Lymphoma, Beijing Boren Hospital, Beijing 100045, China.
Liu Y; Department of Pediatric Lymphoma, Beijing Boren Hospital, Beijing 100045, China.
Zhang YH; Department of Pediatric Lymphoma, Beijing Boren Hospital, Beijing 100045, China.
Pokaż więcej
Źródło :
Zhonghua er ke za zhi = Chinese journal of pediatrics [Zhonghua Er Ke Za Zhi] 2020 Nov 02; Vol. 58 (11), pp. 937-939.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase*/genetics
Lymphoma, Large B-Cell, Diffuse*
Lymphoma, Large-Cell, Anaplastic*
Child ; Family ; Humans
Czasopismo naukowe
Tytuł :
Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer: interim analysis results of a post-marketing surveillance study.
Autorzy :
Kaneda H; Osaka City University, Osaka, Japan.
Kizaki M; Novartis Pharma K.K., Tokyo, Japan.
Ochi M; Novartis Pharma K.K., Tokyo, Japan.
Shiraiwa N; Novartis Pharma K.K., Tokyo, Japan.
Akatsu S; Novartis Pharma K.K., Tokyo, Japan. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 08; Vol. 10 (1), pp. 16773. Date of Electronic Publication: 2020 Oct 08.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Pyrimidines/*therapeutic use
Sulfones/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Anaplastic Lymphoma Kinase/metabolism ; Antineoplastic Agents/adverse effects ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/mortality ; Female ; Humans ; Japan ; Kaplan-Meier Estimate ; Lung Neoplasms/enzymology ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Product Surveillance, Postmarketing ; Progression-Free Survival ; Pyrimidines/adverse effects ; Sulfones/adverse effects
Czasopismo naukowe
Tytuł :
Pharmacological and clinical properties of lorlatinib in the treatment of ALK -rearranged advanced non-small cell lung cancer.
Autorzy :
El Darsa H; Department of Oncology, University of Alberta, Cross Cancer Institute , Edmonton, Canada.
Abdel-Rahman O; Department of Oncology, University of Alberta, Cross Cancer Institute , Edmonton, Canada.
Sangha R; Department of Oncology, University of Alberta, Cross Cancer Institute , Edmonton, Canada.
Pokaż więcej
Źródło :
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2020 Sep; Vol. 21 (13), pp. 1547-1554. Date of Electronic Publication: 2020 Jun 08.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lactams, Macrocyclic/*therapeutic use
Lung Neoplasms/*drug therapy
Anaplastic Lymphoma Kinase/genetics ; Animals ; Brain Neoplasms/drug therapy ; Carcinoma, Non-Small-Cell Lung/enzymology ; Clinical Trials as Topic ; Drug Evaluation, Preclinical ; Humans ; Lung Neoplasms/enzymology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
Autorzy :
Blessing AM; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Santiago-O'Farrill JM; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mao W; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pang L; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ning J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pak D; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Bollu LR; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rask P; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Iles L; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yang H; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tran S; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elmir E; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Bartholomeusz G; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Langley R; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lu Z; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Bast RC Jr; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Aug 01; Vol. 126 (15), pp. 3579-3592. Date of Electronic Publication: 2020 Jun 02.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Anaplastic Lymphoma Kinase/*genetics
Ovarian Neoplasms/*drug therapy
STAT3 Transcription Factor/*genetics
rho GTP-Binding Proteins/*genetics
Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Animals ; Autophagy/drug effects ; Cell Line, Tumor ; Cell Lineage/genetics ; Cell Survival/genetics ; Crizotinib/pharmacology ; Drug Resistance, Neoplasm/genetics ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Heterografts ; Humans ; Mice ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Protein Kinase Inhibitors/pharmacology ; RNA, Small Interfering/genetics ; RNA, Small Interfering/pharmacology ; Signal Transduction/drug effects
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies